AbbVie (NYSE:ABBV) is one of the largest pharmaceutical companies in the world, with a portfolio of drugs aimed at cancers, immune disorders and other serious diseases. Like many public pharmaceutical majors, AbbVie allocates a significant portion of the cash generated from its business to pay above-average dividends to its investors. Today, let’s examine AbbVie stock to see if its dividend and future prospects are enough to make it an attractive buy at current prices.
How High Is AbbVie’s Dividend?
Shares of ABBV are currently yielding about 3.0 percent, an impressive amount when one considers the fact that the S&P 500 is averaging a yield of only 1.1 percent at the moment. AbbVie also has the advantage of being a dividend king, having raised its dividend for 53 consecutive years. Over the past five years, the dividend growth rate has averaged 6.6 percent annually, though the growth rate of the past three years has been a bit slower at 5.2 percent.
How Much Room for Additional Dividend Growth Does AbbVie Have?
Though there’s no doubt that AbbVie offers an attractive yield, investors also have to think about the stock’s potential for future dividend growth. Here, the picture becomes a bit murkier, as AbbVie’s annualized dividend of $6.92 per share massively exceeds its trailing 12-month EPS of $2.36. On an adjusted basis, however, AbbVie reported $10.00 per share in its full-year 2025 earnings report. AbbVie has also generated $10 or more of operating cash flow per share in each year since 2020. As such, the business appears to still be in a decent position to cover its dividend out of its existing cash flows.
With that said, analysts do expect a slower period of dividend growth ahead for AbbVie. Over the upcoming few years, estimates call for a 3.2 percent annualized rate of dividend growth. Even so, AbbVie’s high current yield could make it an appealing choice for income-driven investors in a market currently marked by high stock prices and relatively low yields.
Digging Into AbbVie’s EPS Pop
In 2025, AbbVie was able to grow its revenues by 8.6 percent on a year-over-year basis, bringing total annual revenue to $61.2 billion. This total revenue number, however, masks even more rapid growth among two of AbbVie’s three largest segments. Revenue from its immunology portfolio grew by 14.0 percent to $30.4 billion, while neuroscience revenue rose by 19.6 percent to $10.8 billion. The oncology segment only grew by 1.5 percent to $6.7 billion. The aesthetics portfolio, which includes cosmetic treatments such as Botox, saw its revenues decline by 6.1 percent to $4.9 billion.
Looking forward to 2026, management expects a surge in adjusted EPS to the range of $14.37 to $14.57. This increase in adjusted earnings could put significant upward pressure on ABBV shares, especially if it is accompanied by growth in GAAP earnings. Over the next 3-5 years, analysts are expected AbbVie to deliver compounded annual EPS growth of nearly 18 percent annually.
It’s also worth noting that AbbVie has been investing heavily in acquisitions to build up its pipeline in recent years. Since 2022, the business has conducted 11 acquisitions, including the purchase of Capstan Therapeutics in the middle of last year. These strategic acquisitions have bolstered key parts of AbbVie’s portfolio, and the practice of buying out smaller pharmaceutical firms could continue to benefit AbbVie going forward.
Is AbbVie a Fair Value?
When looking at AbbVie, some investors may be concerned by what appear to be extremely high valuation metrics. ABBV shares are trading at the large multiples of 6.5 times sales and 95.2 times earnings. Here, however, it’s once again important to take into account the very large gap between AbbVie’s GAAP EPS and its adjusted earnings. Even with this factored in, though, AbbVie doesn’t exactly look cheap.
Analysts do still see some upside in ABBV, though. The consensus price target for the stock is $248.29, a price that would imply further gains of 10.4 percent from the most recent price of $224.81. The consensus rating on ABBV is a buy, though the current slate of ratings contains nine holds in addition to 13 buys.
It’s also worth mentioning that AbbVie’s higher-than-average yield likely isn’t indicative of excessive risks, as the stock has managed to maintain fairly high yields over long periods of time. In 2019, for example, AbbVie’s trailing yield was 4.8 percent, well above where it stands today. Indeed, ABBV’s yields have been above their present level for most of the last 10 years. While this may indicate that AbbVie is currently trading at a bit more of a premium than usual, a yield of around 3 percent likely doesn’t signal that AbbVie is either significantly overvalued or undervalued. Taking this fact in conjunction with its current price ratios and analyst forecasts, it appears likely that ABBV is trading at a roughly fair valuation at the moment.
Is AbbVie’s Dividend Worth It?
While the stock does trade at a bit of a high price tag, there’s a great deal to like about AbbVie at the moment. Strong growth in the immunology and neuroscience segments is powering solid overall revenue growth, and the oncology segment could pick up in the coming years as demand for cancer treatments among aging populations grows. With solid long-term earnings growth expected, ABBV could see steady upward pressure on its prices over the next several years.
Where its ability to produce income is concerned, the slower expected period of dividend growth ahead is likely outweighed by the fact that ABBV already yields almost three times the average of the S&P 500. With a strong history of dividend growth behind it, investors are unlikely to see AbbVie break its streak of dividend increases.
While AbbVie may not have the kind of massive growth potential that investors have become accustomed to in tech stocks in recent years, the stock could offer a good balance of strong current dividend income and potential for future growth. As a result, investors who are building dividend growth portfolios may find AbbVie a compelling stock to look at as a buy-and-hold option.
The author has no position in any of the stocks mentioned. Financhill has a disclosure policy. This post may contain affiliate links or links from our sponsors.